Background Image
Menu

News: 2013

Oxford BioTherapeutics and Menarini Progress Enhanced Antibody for Acute Myeloid Leukemia in $1 Billion Oncology Investment Alliance

11 December 2013

Oxford BioTherapeutics and Menarini Progress Enhanced Antibody for Acute Myeloid Leukemia in $1 Billion Oncology Investment Alliance

OXFORD, UK and BERLIN CHEMIE/MENARINI, GERMANY – 9th December 2013 – Oxford BioTherapeutics (OBT) and Berlin-Chemie (Menarini Group) announce today that they have designated a novel enhanced antibody targeting acute myeloid leukemia (AML) as the first clinical...

Zysis Receives US Patent for Long Acting Oral Aripiprazole Once Weekly

14 November 2013

Zysis Receives US Patent for Long Acting Oral Aripiprazole Once Weekly

Portfolio company Zysis, a private pharmaceutical company optimising therapies for disorders of the Central Nervous System, today announced that the United States Patent and Trademark Office has granted U.S. patent 8,575,172 covering its Phase II ready Long Acting Oral...

Technology Strategy Board awards Accutronics £100,000 for medical battery

6 November 2013

Technology Strategy Board awards Accutronics £100,000 for medical battery

Portfolio company Accutronics has received a Smart Award from the UK’s innovation agency, the Technology Strategy Board. The company received a £100,000 grant to support ‘proof of concept’ work on a new high voltage, high capacity battery for the medical...

Patent Published for Lumora’s Novel Sample Preparation Technology

1 November 2013

Patent Published for Lumora’s Novel Sample Preparation Technology

Cambridgeshire, UK, 31 October 2013 ... Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial market, has received a patent for its Heat Elution Sample Preparation, technology which has the potential to help commercial laboratories...

PolyTherics and TUBE Pharma collaborate to develop novel cytotoxic payloads for antibody drug conjugates (ADCs)

18 October 2013

PolyTherics and TUBE Pharma collaborate to develop novel cytotoxic payloads for antibody drug conjugates (ADCs)

London, UK and Vienna, Austria, 15 October 2013 - PolyTherics Limited (“PolyTherics”) and TUBE Pharma GmbH (“TUBE”) announce that they are collaborating to produce reagents to link novel cytotoxic drugs developed by TUBE to antibodies using...

Innovative new Blade Inspection System launched

16 October 2013

Innovative new Blade Inspection System launched

Limpet Technology has signed an exclusive 2-year agreement with portfolio company RTS International to provide an innovative blade and turbine inspection system using the skills and expertise from each company. The signatures mark the end of a 2 year R&D Project initiated by...

Probe Scientific signs new licensing deal with Menarini

17 September 2013

Probe Scientific signs new licensing deal with Menarini

Emerging UK medical device developer Probe Scientific Ltd has secured a licensing deal for its revolutionary MicroEye® technology with multi-national organisation A. Menarini Diagnostics. After successfully trialling MicroEye®, the Italian based organisation has paid an...

Zinwave in-building wireless system interfaces with managed access systems deployed by the military and correctional institutions

29 August 2013

Zinwave in-building wireless system interfaces with managed access systems deployed by the military and correctional institutions

Zinwave Ltd, a global provider of wideband active distributed antenna systems (DAS) for in-building wireless coverage, is supporting the deployment of managed access systems in correctional facilities, border checkpoints and military bases to prevent unauthorised cell phone...

Catapult makes key appointment

28 August 2013

Catapult makes key appointment

Jonathan Lowe has joined Catapult Venture Managers as an Investment Director. He joins the company from Capital for Enterprise Limited (CfEL), where he was a Portfolio Director. Jonathan began his career as a relationship manager for NatWest in Nottingham, but it is...

No Photo

27 August 2013

Biofortuna raises £1.3m of investment for growth in its freeze-dried molecular diagnostics business and service provision

Portfolio company Biofortuna, a UK based molecular diagnostics company with a proprietary stabilisation technology for molecular reagents, is expanding its custom service and manufacturing business with a £1.3m investment. The new funds will enable the business to expand...